Uncategorized

Evidence-first preconception advice for people with obesity or PCOS: how semaglutide affects ovulation, what studies and labels show, and why a 2 month…

Clinician brief: semaglutide’s small gallbladder risk (about 1 in 60–100). Trial/FDA data and telehealth screening steps in first 90 days.

Clinician review of BPC-157 benefits: strong animal evidence, only one human trial, FDA and WADA concerns, and why supervised care matters.

Evidence-first review for clinicians: transdermal physiologic dose testosterone is supported only for postmenopausal HSDD. Covers dosing, monitoring, and…

Evidence first clinician summary of bioidentical hormone therapy: separates marketing myths, summarizes guidance, and explains telehealth.

Evidence first explainer on Reverse T3 for clinicians and patients: why high values usually reflect illness, when testing helps, and five steps clinicians…

Clinician aligned stepwise plan to relieve semaglutide constipation: lifestyle first, gradual fiber, movement, OTC osmotics, daily routines, and when to…

Evidence-based perimenopause hormone therapy: when to start (within 10 years or before age 60), benefits, risks, nonhormonal options, and clinician-guided…

U.S. safety-first semaglutide dosing: start 0.25 mg weekly and follow a 4 week titration per FDA labels. Learn vial conversion checks and when to seek…

What six oral trials (about 900 people) showed, why the FDA flagged compounded AOD‑9604, and four clinician checks to vet any offer.